A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients

Trial Profile

A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Avibactam/ceftazidime (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Pneumonia; Skin infections; Soft tissue infections; Urinary tract infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Oct 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
    • 31 Oct 2016 Planned initiation date changed from 1 Jul 2016 to 1 Jan 2017.
    • 14 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top